Synthesis and biological activity of raltitrexed-carrier conjugates

Acta Biochimica Polonica

Volumn 57, Issue 1, 2010, Pages 83-87

  Jagiello, Monika ^a   Kanska, Urszula ^a   Nevozhay, Dmitry ^a   Boratynski, Janusz ^a,b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b JAN DLUGOSZ UNIVERSITY   (Poland)

Author keywords

Carrier; Conjugate; Raltitrexed; Thymidylate synthase; Tomudex

Indexed keywords

BOVINAE;

BOVINE SERUM ALBUMIN; DEXTRAN; LYSOZYME; QUINAZOLINE DERIVATIVE; RALTITREXED; THIOPHENE DERIVATIVE;

ANIMAL; APOPTOSIS; ARTICLE; CANCER TRANSPLANTATION; CATTLE; CELL CYCLE; CHEMISTRY; DRUG EFFECT; HUMAN; MOUSE; PH; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CATTLE; CELL CYCLE; CELL LINE, TUMOR; DEXTRANS; HUMANS; HYDROGEN-ION CONCENTRATION; MICE; MURAMIDASE; NEOPLASM TRANSPLANTATION; QUINAZOLINES; SERUM ALBUMIN, BOVINE; THIOPHENES;

EID: 77953235464     PISSN: 0001527X     EISSN: 1734154X     Source Type: Journal    
DOI: 10.18388/abp.2010_2376     Document Type: Article

References (24)

1. Bolling C, Graefe T, Lubbing C, Jankevicius F, Uktveris S, Cesas A, Meyer-Moldenhauer WH, Starkmann H, Weigel M, Burk K, Hanauske AR (2006) Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. Invest New Drugs 24: 521-527.
2. Boratynski J, Opolski A, Wietrzyk J, Gorski A, Radzikowski C (2000) Cytotoxic and antitumor effect of fibrinogen-methotrexate conjugate. Cancer Lett 148: 189-195.
3. Boratynski J (1984) Colorimetric method for the determination of ketoses using phenol-acetone-boric acid reagent (PABR). Anal Biochem 137: 528-532.
4. Budzynska R, Nevozhay D, Kanska U, Jagiello M, Opolski A, Wietrzyk J, Boratynski J (2007) Antitumor activity of mannan-methotrexate conjugate in vitro and in vivo. Oncol Res 16: 415-421.
5. Burger AM, Hartung G, Stehle G, Sinn H, Fiebig HH (2001) Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. Int J Cancer 92: 718-724.
6. Ghose T, Norvell ST, Guclu A, Cameron D, Bodurtha A, MacDonald AS (1972) Immunochemotherapy of cancer with chlorambucil carrying antibody. Br Med J 3: 495-499.
7. Hartung G, Stehle G, Sinn H, Wunder A, Schrenk HH, Heeger S, Kranzle M, Edler L, Frei E, Fiebig HH, Heene DL, Maier-Borst W, Queisser W (1999) Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I study group of the association for medical oncology of the German cancer society. Clin Cancer Res 5: 753-759.
8. Kanska U, Omar MS, Budzynska R, Nevozhay D, Jagiello M, Opolski A, Boratynski J (2005) Antileukemic activity of glycated fibrinogenmethotrexate conjugates. Anticancer Res 25: 2229-2234.
9. Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132: 171-183.
10. Li KL, Clarke SJ, Rivory LP (2003) Quantitation of plasma thymidine by high-performance liquid chromatography - atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. Anal Chim Acta 486: 51-61.
11. Mathe G, Loc T, Bernard J (1958) Effect sur la leucemie 1210 de la souris d'une combinaison par diazotation d'A-methopterine et da γ-globulines de hamsters porteurs de cette leucmie par heterograffe. CR Acad Sci (Paris) 246: 1626-1630.
12. McGuire JJ (2003) Anticancer antifolates: current status and future directions. Curr Pharm Des 9: 2593-2613.
13. Myc A, Kukowska-Latallo J, Cao P, Swanson B, Battista J, Dunham T, Baker JR Jr (2010) Targeting the efficacy of a dendrimer-based nanotherapeutic in heterogeneous xenograft tumors in vivo. Anticancer Drugs 21: 186-192.
14. Nevozhay D, Budzynska R, Jagiello M, Kanska U, Omar MS, Opolski A, Wietrzyk J, Boratynski J, Opolski, A (2006a) The effect of the substitution level of some dextran-methotrexate conjugates on their antitumor activity in experimental cancer models. Anticancer Res 26: 2179-2186.
15. Nevozhay D, Budzynska R, Kanska U, Jagiello M, Omar MS, Boratynski J, Opolski A (2006b) Antitumor properties and toxicity of dextran-methotrexate conjugates are dependent on the molecular weight of the carrier. Anticancer Res 26: 1135-1143.
16. Nevozhay D, Kanska U, Budzynska R, Boratynski J (2007) Current status of research on conjugates and related drug delivery systems in the treatment of cancer and other diseases. Postepy Hig Med Dosw 61: 350-360.
17. Riebeseel K, Biedermann E, Loser R, Breiter N, Hanselmann R, Mulhaupt R, Unger C, Kratz F (2002) Polyethylene glycol conjugates of methotrexate varying in their molecular weight from MW 750 to MW 40000: synthesis, characterization, and structure-activity relationships in vitro and in vivo. Bioconjug Chem 13: 773-785.
18. Silverstein AM (1999) Paul Ehrlich's passion: the origins of his receptor. Immunol Cell Immunol 194: 213-221.
19. Skehan P, Storeng R, Scudiero D, Monks A, McMahn J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112.
20. Stehle G, Wunder A, Sinn H, Schrenk HH, Schutt S, Frei E, Hartung G, Maier-Borst W, Heene DL (1997) Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats. Anticancer Drugs 8: 835-844.
21. Stehle G, Wunder A, Schrenk HH, Hartung G, Heene DL, Sinn H (1999) Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 HI prostate cancer-bearing rats. Anticancer Drugs 10: 405-411.
22. Wilson KS, Malfair Taylor SC (2009) Raltitrexed: optimism and reality. Expert Opin Drug Metab Toxicol 5: 1447-1454.
23. Wunder A, Stehle G, Schrenk HH, Hartung G, Heene DL, Maier-Borst W, Sinn H (1998) Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma. Int J Cancer 76: 884-890.
24. Yousefi G, Foroutan SM, Zarghi A, Shafaati A (2010) Synthesis and characterization of methotrexate polyethylene glycol esters as a drug delivery system. Chem Pharm Bull (Tokyo) 58: 147-153.